Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen: what's new in 1997

J Pannek1, A W Partin

  • 1Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institution, Baltimore, Maryland, USA.

Oncology (Williston Park, N.Y.)
|October 27, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Rehabilitation after Spinal Cord Injury : Current trends and principles].

Unfallchirurgie (Heidelberg, Germany)·2023
Same author

[Course of neurogenic bladder dysfunction in patients with spinal cord injury under homeopathic treatment].

Der Urologe. Ausg. A·2020
Same author

[Use of synthetic slings and mesh implants in the treatment of female stress urinary incontinence and prolapse : Statement of the Working Group on Urological Functional Diagnostics and Female Urology of the Academy of the German Society of Urology].

Der Urologe. Ausg. A·2019
Same author

[Erratum to: Overactive bladder-which treatment when?]

Der Urologe. Ausg. A·2018
Same author

[Overactive bladder-which treatment when?]

Der Urologe. Ausg. A·2017
Same author

The effects of antimuscarinic treatment on the cognition of spinal cord injured individuals with neurogenic lower urinary tract dysfunction: a prospective controlled before-and-after study.

Spinal cord·2017

Prostate-specific antigen (PSA) alone is insufficient for prostate cancer detection. Optimizing PSA use involves velocity, density, and molecular forms, with human kallikrein 2 (hK2) showing promise as a new marker.

Area of Science:

  • Oncology
  • Biochemistry
  • Urology

Background:

  • Prostate-specific antigen (PSA) is a key biomarker for prostate cancer.
  • However, its standalone use for early detection and staging has limitations in sensitivity and specificity.

Purpose of the Study:

  • To explore methods for optimizing the clinical utility of PSA in prostate cancer diagnosis.
  • To evaluate novel biomarkers and molecular techniques for improved prostate cancer detection.

Main Methods:

  • Analysis of PSA velocity, PSA density, and age-related PSA reference ranges.
  • Assessment of molecular PSA forms, including free PSA percentage.
  • Investigation of advanced molecular techniques like RT-PCR for PSA mRNA detection.
  • Evaluation of human kallikrein 2 (hK2) as a potential prostate cancer marker.

Related Experiment Videos

Main Results:

  • PSA velocity offers good results but requires serial measurements.
  • PSA density depends on accurate prostatic volume assessment via TRUS.
  • Age-specific PSA ranges show better sensitivity in younger men.
  • Free PSA percentage aids detection in men with borderline total PSA.
  • RT-PCR can detect minimal PSA mRNA levels.
  • hK2 demonstrates potential as a novel prostate cancer biomarker.

Conclusions:

  • Optimizing PSA interpretation through velocity, density, and molecular forms enhances its diagnostic value.
  • Emerging molecular markers like hK2 and advanced techniques like RT-PCR hold significant promise for future prostate cancer diagnostics.